Non-hodgkin's%20lymphoma News

News

CAR T-cell therapy makes it to the clinic in Hong Kong

Christina Lau, 20210309025728

Haematologists from the University of Hong Kong (HKU) have reported initial success with chimeric antigen receptor (CAR) T-cell therapy, treating the first patient in Hong Kong in May 2020 in a global lymphoma trial and another leukaemia patient in October 2020 in a real-world clinical practice setting.

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)

20210105000000

New drug applications approved by US FDA as of 16 - 31 December 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

COVID-19 recommendations in 23 languages for cancer patients

Christina Lau, 20200707054248

Comprehensive recommendations on coronavirus disease 2019 (COVID-19) for cancer patients have become available following review of guidelines from 63 national/international oncology societies. [Lancet Oncol 2020, doi: 10.1016/S1470-2045(20)30278-3]

AF risk elevated in certain cancers

Roshini Claire Anthony, 20200406140003

The risk of atrial fibrillation (AF) appears to be elevated among patients with a history of cancer, particularly those with prostate cancer, according to a study presented at ACC.20.

No link between anti-TNF agents and lymphoma in paediatric IBD

Roshini Claire Anthony, 20200212140101

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Original New Drug Application Approvals by US FDA (16 - 31 July 2019)

20190731000000

New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

$Novel anti-CD47 immunotherapy shows promise in relapsed/refractory lymphoma$

Novel anti-CD47 immunotherapy shows promise in relapsed/refractory lymphoma

Christina Lau, 20190710130955

A first-in-class immunoglobulin G4 (IgG4) antibody targeting CD47 has demonstrated durable responses when used in combination with rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or indolent lymphoma.

Pesticide chemical ups non-Hodgkin lymphoma risk in Asians

Tristan Manalac, 20190426075259

There appears to be a positive and significant link between non-Hodgkin lymphoma risk in Asians and blood concentration of β-hexachlorocyclohexane, an organochloride used in many pesticides, according to a new study.

Antiviral therapy with interferon, ribavirin cuts risk of HCV-related lymphoma

Jairia Dela Cruz, 20190124110000

Antiviral treatment with pegylated interferon and ribavirin leads to a significant reduction in the risk of lymphoma, especially the non-Hodgkin’s type, in patients with chronic hepatitis C virus (HCV) infection, according to a study.

$Tisagenlecleucel shows high rates of durable responses in adults with relapsed/refractory DLBCL$

Tisagenlecleucel shows high rates of durable responses in adults with relapsed/refractory DLBCL

Christina Lau, 20190109065153

The anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel has demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the pivotal international JULIET study.

New treatment option now available for patients with HR+/HER2- aBC/MBC, PIK3CA mutations

31 Mar 2021

At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT^®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.

Immunotherapy sparks hope for paediatric ALL

Audrey Abella, 14 Oct 2020

Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).